Augustine Asset Management Inc. Makes New Investment in United Therapeutics Corporation $UTHR

Key Points

• Augustine Asset Management Inc. has made a new investment in United Therapeutics Corporation by acquiring 5,282 shares, valued at approximately $1,518,000, during the 2nd quarter.
• United Therapeutics reported $6.41 EPS for the quarter, missing expectations, despite a year-over-year revenue increase of 11.7% to $798.60 million.
• Analysts are optimistic about the company, with UBS Group raising its price target from $415 to $560, and ten investment analysts rating the stock as a "Buy."

Augustine Asset Management Inc. acquired a new position in shares of United Therapeutics Corporation (NASDAQ:UTHR - Free Report) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 5,282 shares of the biotechnology company's stock, valued at approximately $1,518,000.

Other institutional investors also recently bought and sold shares of the company. XTX Topco Ltd purchased a new stake in United Therapeutics during the 1st quarter worth $313,000. Allianz Asset Management GmbH boosted its position in shares of United Therapeutics by 96.9% in the first quarter. Allianz Asset Management GmbH now owns 67,576 shares of the biotechnology company's stock worth $20,832,000 after buying an additional 33,254 shares during the period. LPL Financial LLC boosted its position in shares of United Therapeutics by 77.3% in the first quarter. LPL Financial LLC now owns 25,246 shares of the biotechnology company's stock worth $7,783,000 after buying an additional 11,007 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its holdings in United Therapeutics by 11.4% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,678 shares of the biotechnology company's stock worth $1,129,000 after acquiring an additional 376 shares during the period. Finally, Concurrent Investment Advisors LLC purchased a new position in United Therapeutics in the 1st quarter worth approximately $227,000. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

United Therapeutics Price Performance

NASDAQ UTHR opened at $432.66 on Friday. United Therapeutics Corporation has a 12 month low of $266.98 and a 12 month high of $442.01. The company's fifty day moving average price is $342.90 and its two-hundred day moving average price is $314.73. The company has a market capitalization of $19.52 billion, a price-to-earnings ratio of 16.89, a price-to-earnings-growth ratio of 6.48 and a beta of 0.62.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 EPS for the quarter, missing the consensus estimate of $6.80 by ($0.39). United Therapeutics had a return on equity of 18.73% and a net margin of 40.36%.The company had revenue of $798.60 million for the quarter, compared to the consensus estimate of $802.13 million. During the same period in the previous year, the business posted $5.85 EPS. The business's revenue for the quarter was up 11.7% on a year-over-year basis. As a group, analysts anticipate that United Therapeutics Corporation will post 24.48 EPS for the current year.

Insider Buying and Selling

In other news, COO Michael Benkowitz sold 22,500 shares of United Therapeutics stock in a transaction dated Tuesday, September 2nd. The shares were sold at an average price of $417.64, for a total value of $9,396,900.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Paul A. Mahon sold 11,000 shares of United Therapeutics stock in a transaction dated Thursday, August 21st. The shares were sold at an average price of $308.75, for a total transaction of $3,396,250.00. Following the completion of the transaction, the executive vice president directly owned 36,781 shares of the company's stock, valued at $11,356,133.75. This trade represents a 23.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 192,935 shares of company stock worth $73,905,462. 10.30% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of research firms have weighed in on UTHR. UBS Group upped their price target on United Therapeutics from $415.00 to $560.00 and gave the stock a "buy" rating in a report on Thursday, September 4th. JPMorgan Chase & Co. decreased their target price on shares of United Therapeutics from $350.00 to $330.00 and set an "overweight" rating for the company in a research note on Tuesday, July 8th. Royal Bank Of Canada initiated coverage on shares of United Therapeutics in a research report on Friday. They issued an "outperform" rating and a $569.00 price objective for the company. Wells Fargo & Company upped their price objective on shares of United Therapeutics from $295.00 to $414.00 and gave the company an "equal weight" rating in a research report on Wednesday, September 3rd. Finally, Morgan Stanley reduced their price target on United Therapeutics from $348.00 to $328.00 and set an "equal weight" rating for the company in a report on Thursday, July 10th. Ten investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $448.14.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.